Alzheimer's disease

Faced with slowing demand for Humira following the launch of biosimilar versions in the US, AbbVie this year bought neuroscience drug developer Cerevel Therapeutics and cancer drug developer ImmunoGen in deals worth around US$19 billion in total.

Consumer & Healthcare

AbbVie to buy Alzheimer's therapy developer Aliada for US$1.4 billion

The Aliada deal is expected to close by the end of this year

2024-10-28T15:13:00.000Z

MRI scans are required to monitor for early signs of side effects of Leqembi that can include brain bleeding and swelling.

Consumer & Healthcare

What you should know about the newest Alzheimer’s drugs

While humans are living longer – a child born in 2021 on average could expect to live to 71 – we have not figured out how to beat one of the worst scourges of aging: Alzheimer’s disease.

2024-06-12T15:30:00.000Z

Lilly’s drug, donanemab is an intravenous antibody designed to remove deposits of a protein called beta amyloid from the brains of Alzheimer’s patients.

International

Lilly Alzheimer drug faces more delays as FDA plans hearing

Eli Lilly’s Alzheimer’s disease drug donanemab faces further delays in gaining approval, with US regulators planning to hold a hearing of external advisers to explore how safe the therapy is and how w...

2024-03-08T12:57:36.000Z

Latest T-bills Treasury Bills Results & Interest News Latest SSB Singapore Savings Bonds News Latest COE Certificate of Entitlement News

Latest Johor-Singapore SEZ News Latest BTO Build To Order & Sales of Balance News Latest STI Straits Times Index News Latest SGX Dividends, Share Price News Latest Bonds Market News Latest Singapore Stocks To Buy News Latest Singapore Economy News